This is an oral medication in tablet form.
Ponvory is a selective sphingosine 1-phosphate receptor 1 modulator. It is thought to act by promoting the retention of certain white blood cells in the body’s lymph nodes, keeping them out of circulation and from entering the brain and spinal cord.
Ponvory is approved by the FDA for relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS), and active secondary progressive disease, in adults.
Read the Society's news bulletin on the FDA approval of Ponvory here
to read the Ponvory Prescribing Information for healthcare professionals.
to read the Ponvory Medication Guide for patients (scroll to page 30).
This medication is expected to be available April 2021. Information on availability, cost, and patient support programs will be provided when they become available.